Mitsubishi Tanabe Pharma's US commercial infrastructure and ¥80 billion US revenue target
First written in FY2018-Q1. 2 of 6 entries say "Advanced", first in FY2018-Q2. Latest entry: FY2019.
No other company in this theme has enough history to compare yet.
- FY2019DroppedAnnual report
「In Pharmaceuticals, Radicava, a treatment for amyotrophic lateral sclerosis (ALS), grew in the US, but revenue declined in domestic prescription pharmaceuticals due to the drug price revision implemented in April 2018 and lower royalty income, among other factors.」
This filing does not confirm the previously stated ¥80 billion US revenue target by FY2020 or an explicit statement regarding the feasibility of achieving it; it only reports Radicava sales results. - FY2019-Q3RestatedAnnual report
「In pharmaceuticals, sales revenue and core operating profit both declined due to the April 2018 drug price revision, the October 2017 transfer of the generic drug business, and other factors affecting domestic prescription drugs, despite growth in US sales of Radicava, a treatment for amyotrophic lateral sclerosis (ALS).」
The Company continues to report growth in Radicava sales as it builds its own US commercial infrastructure. In Japan, pharmaceutical revenue and profit declined due to drug price revisions and the transfer of the generic business, among other factors. - FY2018AdvancedAnnual report
「Pharmaceuticals revenue increased despite a decline due to the transfer of the generic business and other factors, as priority products such as Simponi, a treatment for rheumatoid arthritis, grew, and Radicava, a treatment for amyotrophic lateral sclerosis (ALS), grew substantially in the US, among other factors.」
The Company reports progress toward the ¥80 billion FY2020 US revenue target through substantial growth in Radicava sales as it builds its own US commercial infrastructure, together with ND0612 acquired through the acquisition of NeuroDerm. - FY2018-Q3RestatedAnnual report
「Pharmaceutical revenue increased due to growth in domestic sales of prescription drugs and the steady performance of sales of RADICAVA, an ALS treatment launched in the United States in August, among other factors.」
The Company states that sales of Radicava toward establishing its own US commercial infrastructure have progressed smoothly. The ¥80 billion US revenue target for FY2020 itself remains unchanged. - FY2018-Q2AdvancedAnnual report
「As its first step, the Company began selling Radicava, a treatment for amyotrophic lateral sclerosis (ALS), in the US market in August 2017. In addition, the acquisition of ND0612 through the acquisition of NeuroDerm is expected to make it possible to achieve the medium-term management plan target of ¥80 billion in US revenue by FY2020.」
To establish its own US commercial infrastructure, the Company began selling Radicava in the US and acquired ND0612 through the acquisition of NeuroDerm. The relationship with the target of ¥80 billion in US revenue by FY2020 continues to be stated explicitly. - FY2018-Q1First statedAnnual report
「Mitsubishi Tanabe Pharma Corporation, a consolidated subsidiary of the Company, aims to establish at an early stage a sustainable growth platform based on direct sales in order to grow mainly in the US, the world's largest pharmaceutical market, under its Medium-Term Management Plan 16-20, "Open Up the Future." As its first step, it plans to begin selling Radicava, a treatment for amyotrophic lateral sclerosis (ALS), in the US market in August 2017. In addition, the acquisition of ND0612 through the acquisition of NeuroDerm is expected to make it possible to achieve the medium-term management plan target of ¥80 billion in US revenue by FY2020.」
The Company presents for the first time, as a separate theme, a plan for Mitsubishi Tanabe Pharma to establish its own US commercial infrastructure and target ¥80 billion in US revenue by FY2020 through the launch of Radicava sales and the acquisition of ND0612 through the acquisition of NeuroDerm.